Details for Patent: 11,426,390

Which drugs does patent 11,426,390 protect, and when does it expire?

Patent 11,426,390 protects QINLOCK and is included in one NDA.

This patent has twenty-one patent family members in twelve countries.

Summary for Patent: 11,426,390

Title:	Methods of treating gastrointestinal stromal tumors
Abstract:	The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.
Inventor(s):	Soto; Rodrigo Ruiz (Waltham, MA), Rosen; Oliver (Waltham, MA), Pitman; Jama (Waltham, MA)
Assignee:	Deciphera Pharmaceuticals, LLC (Waltham, MA)
Application Number:	17/583,977
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 11,426,390

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Deciphera Pharms	QINLOCK	ripretinib	TABLET;ORAL	213973-001	May 15, 2020		RX	Yes	Yes						TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN PATIENTS BEING TREATED CONCURRENTLY WITH A CYP3A4 INHIBITOR

International Family Members for US Patent 11,426,390

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	122301
Australia	2020328538
Australia	2020329956
Australia	2023286024